Venus Concept has received approval for the Venus Bliss MAX from the State of Israel Ministry of Health. The Venus Bliss MAX was first launched commercially in the United States in Q1 2022 after FDA 510(k) clearance and offered internationally in approved jurisdictions. The Venus Bliss MAX offers three advanced technologies in one platform: diode laser applicators, (MP)2 applicator that combines Multi-Polar Radio Frequency and Pulsed Electro Magnetic Fields with advanced VariPulse technology and the Company’s FlexMax EMS applicators. This advanced three-in-one platform enables practitioners to offer treatments for non-invasive lipolysis of the abdomen, flanks, back, and thighs, relief of muscle aches and pain, relief of muscle spasms, improvement in blood circulation, reduction in the appearance of cellulite and for muscle conditioning to stimulate healthy muscles.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERO:
- Venus Concept files to sell 875K shares of common stock for holders
- Australian regulator approves Venus Versa Pro
- Venus Concept Announces Australian Regulatory Approval for Venus Versa Pro
- Venus Concept’s Operations Under Threat: Geopolitical Tensions in Israel Pose Risks to Business Continuity
- Venus Concept reports Q4 EPS ($2.01), consensus ($1.18)
